Lyell Immunopharma LYEL Balance Sheet (2020-2026)

NASDAQ LYEL
$14.40 +0.08 (+0.56%)
As of: Sep 4, 2026 · 2:47 PM EDT
Reported Financials

Lyell Immunopharma Quarterly Balance Sheet

Periods 25 quarters
Latest Jun 2026

Lyell Immunopharma reported total assets of $311.15M and total liabilities of $77.34M for the quarter ended Jun 2026, down 19.3% year over year. This balance sheet covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
393.50M293.83M222.60M205.74M116.31M123.55M109.43M224.37M286.21M145.65M125.65M133.42M100.30M105.60M120.33M98.80M123.58M60.18M90.77M72.98M
Prepaid Assets
12.23M11.49M11.79M11.21M11.61M11.14M11.63M10.66M11.42M8.46M7.87M8.71M9.50M9.07M8.00M5.42M8.58M13.72M13.28M9.44M
Current Assets
631.15M626.29M625.71M666.78M659.75M651.29M624.40M606.41M586.85M554.69M534.16M499.82M450.05M379.59M309.18M282.21M328.20M260.94M267.30M213.54M
Non-Current Assets
Property, Plant & Equipment (Net)
115.86M120.10M125.71M127.56M125.73M123.02M118.60M113.68M108.10M102.65M97.84M93.10M88.05M48.20M44.20M39.12M36.72M34.77M32.72M30.51M
Long-Term Investments
317.51M283.53M224.12M131.44M102.52M70.12M55.26M36.95M32.00M32.00M19.00M19.00M20.11M19.00M28.95M20.06M19.00M19.00M19.00M23.90M
Other Non-Current Assets
0.47M0.47M0.28M0.28M0.28M0.28M0.28M0.28M0.28M0.28M0.29M0.29M0.29M4.62M1.69M1.58M2.54M4.89M5.23M5.84M
Non-Current Assets
567.19M501.12M446.40M354.90M317.52M286.27M256.05M228.94M208.13M195.34M160.06M154.32M169.17M111.27M120.62M103.24M79.76M79.11M83.32M97.61M
Assets
1,198.33M1,127.41M1,072.10M1,021.67M977.27M937.56M880.45M835.35M794.99M750.03M694.22M654.14M619.22M490.86M429.80M385.45M407.96M340.05M350.63M311.15M
Liabilities
Current Liabilities
Accounts Payables
3.53M3.21M6.51M4.25M4.79M3.92M5.73M5.80M4.37M4.82M4.89M4.20M3.60M5.37M3.73M3.38M2.57M2.89M5.47M3.88M
Payables
3.53M3.21M6.51M4.25M4.79M3.92M5.73M5.80M4.37M4.82M4.89M4.20M3.60M5.37M3.73M3.38M2.57M2.89M5.47M3.88M
Accumulated Expenses
25.06M29.06M22.69M21.40M23.57M28.75M22.42M24.83M29.65M28.13M24.91M25.67M29.01M40.82M31.17M28.00M29.31M46.52M31.48M35.99M
Current Deferred Revenue
5.58M4.99M6.22M15.43M11.19M
Total Current Liabilities
59.28M46.74M41.05M50.29M51.22M37.03M30.80M34.39M35.06M34.52M32.35M30.88M33.51M53.79M41.28M36.90M31.88M49.41M36.95M39.87M
Non-Current Liabilities
Non-Current Deffered Revenue
81.88M79.67M77.87M32.93M37.16M
Preferred Stock Liabilities
Operating Leases
65.68M66.65M68.81M67.55M67.47M63.17M66.64M66.07M64.64M56.89M61.83M60.22M58.58M50.99M57.09M55.11M53.07M41.92M48.85M46.60M
Other Non-Current Liabilities
5.01M4.57M4.45M4.34M4.23M4.11M4.00M3.89M3.78M3.66M3.55M3.44M3.56M7.60M6.39M5.53M2.68M0.52M0.53M0.54M
Total Non-Current Liabilities
206.85M193.05M186.40M149.29M153.02M100.20M92.62M94.61M93.64M91.41M87.51M84.20M84.95M100.44M86.89M81.00M76.16M91.33M76.43M76.80M
Total Liabilities
211.86M197.62M190.85M153.63M157.24M104.31M96.62M98.50M97.42M95.08M91.06M87.64M88.52M108.03M93.28M86.53M78.84M91.85M76.96M77.34M
Shareholder's Equity
Common Equity
986.47M929.79M881.25M868.04M820.03M833.25M783.83M736.86M697.57M654.95M603.16M566.50M530.70M382.82M336.52M298.92M329.12M248.20M273.67M233.81M
Liabilities and Shareholders Equity
1,198.33M1,127.41M1,072.10M1,021.67M977.27M937.56M880.45M835.35M794.99M750.03M694.22M654.14M619.22M490.86M429.80M385.45M407.96M340.05M350.63M311.15M
Retained Earnings
-500.66M1,515.75M1,540.33M1,565.20M1,589.08M1,608.31M1,622.12M1,637.54M1,647.91M1,657.13M1,666.32M1,675.46M1,683.08M1,727.64M1,733.63M1,738.85M1,807.75M1,867.51M1,917.38M1,922.43M
Preferred Shares
10.00M
Treasury Shares